{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:37:48Z","timestamp":1784875068132,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.josat.2025.209725","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T15:35:07Z","timestamp":1748446507000},"page":"209725","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Prescription opioid spillovers: Retail pharmacy level analysis"],"prefix":"10.1016","volume":"175","author":[{"given":"Collin D.","family":"Hodges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shishir","family":"Shakya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2025.209725_bb0005","series-title":"How an epic legal battle brought a secret drug database to light","author":"Achenbach","year":"2019"},{"key":"10.1016\/j.josat.2025.209725_bb0010","series-title":"The prescription opioid epidemic: An evidence-based approach","author":"Alexander","year":"2015"},{"issue":"2","key":"10.1016\/j.josat.2025.209725_bb0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1073110518782948","article-title":"The impact of prescription drug monitoring programs on U.S. opioid prescriptions","volume":"46","author":"Ayres","year":"2018","journal-title":"Journal of Law, Medicine and Ethics"},{"issue":"10","key":"10.1016\/j.josat.2025.209725_bb0020","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1377\/hlthaff.2018.0512","article-title":"Assessing the impact of state policies for prescription drug monitoring programs on high-risk opioid prescriptions","volume":"37","author":"Bao","year":"2018","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2025.209725_bb0025","series-title":"IZA discussion paper 10990","article-title":"The mitigating role of prescription drug monitoring programs in the abuse of prescription drugs","author":"Birk","year":"2017"},{"issue":"2","key":"10.1016\/j.josat.2025.209725_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/003335491412900207","article-title":"Prescription drug monitoring and dispensing of prescription opioids","volume":"129","author":"Brady","year":"2014","journal-title":"Public Health Reports"},{"issue":"1","key":"10.1016\/j.josat.2025.209725_bb0035","first-page":"77","article-title":"The effect of prescription drug monitoring programs on opioid utilization in Medicare","volume":"10","author":"Buchmueller","year":"2018","journal-title":"American Economic Journal: Economic Policy"},{"issue":"49","key":"10.1016\/j.josat.2025.209725_bb0040","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1073\/pnas.1518393112","article-title":"Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century","volume":"112","author":"Case","year":"2015","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.josat.2025.209725_bb0045","series-title":"Prescription drug monitoring programs: What states need to know","author":"CDC","year":"2021"},{"key":"10.1016\/j.josat.2025.209725_bb0050","series-title":"U.S. overdose deaths in 2021 increased half as much as in 2020 \u2013 But are still up 15%","author":"Centers for Disease Control and Prevention","year":"2022"},{"key":"10.1016\/j.josat.2025.209725_bb0055","series-title":"Provisional data shows U.S. drug overdose deaths top 100,000 in 2022","author":"Centers for Disease Control and Prevention","year":"2023"},{"key":"10.1016\/j.josat.2025.209725_bb0060","series-title":"Prescription drug monitoring programs, opioid abuse, and crime. Working paper 24975","author":"Dave","year":"2018"},{"key":"10.1016\/j.josat.2025.209725_bb0065","series-title":"The US opidemic: Prescription opioids, labour market conditions and crime. MPRA paper, University Library of Munich, Germany","author":"Deiana","year":"2018"},{"issue":"1","key":"10.1016\/j.josat.2025.209725_bb0070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/pam.22098","article-title":"Mandatory access prescription drug monitoring programs and prescription drug abuse","volume":"38","author":"Grecu","year":"2019","journal-title":"Journal of Policy Analysis and Management"},{"issue":"9","key":"10.1016\/j.josat.2025.209725_bb0075","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jama.2014.18514","article-title":"Mandatory use of prescription drug monitoring programs","volume":"313","author":"Haffajee","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2025.209725_bb0080","series-title":"Drug overdose deaths in the United States, 1999\u20132020","author":"Hedegaard","year":"2021"},{"key":"10.1016\/j.josat.2025.209725_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1393","article-title":"Opioid prescribing by multiple providers in Medicare: retrospective observational study of insurance claims","volume":"348","author":"Jena","year":"2014","journal-title":"BMJ"},{"issue":"20","key":"10.1016\/j.josat.2025.209725_bb0090","first-page":"2040","article-title":"Massive costs of the US opioid epidemic in lives and dollars","volume":"325","author":"Kuehn","year":"2021","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.josat.2025.209725_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/add.13620","article-title":"Physician attitudes and experiences with Maryland\u2019s prescription drug monitoring program (pdmp)","volume":"112","author":"Lin","year":"2017","journal-title":"Addiction"},{"key":"10.1016\/j.josat.2025.209725_bb0100","series-title":"Economic studies on the opioid crisis: A review. National Bureau of Economic Research, Working Paper 28067","author":"Maclean","year":"2022"},{"issue":"1","key":"10.1016\/j.josat.2025.209725_bb0105","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMsa1514387","article-title":"State legal restrictions and prescription-opioid use among disabled adults","volume":"375","author":"Meara","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.josat.2025.209725_bb0110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1162\/ajhe_a_00101","article-title":"Prescription drug monitoring programs: The role of asymmetric information on drug availability and abuse","volume":"4","author":"Meinhofer","year":"2018","journal-title":"American Journal of Health Economics"},{"key":"10.1016\/j.josat.2025.209725_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109759","article-title":"Mandatory prescription drug monitoring programs and overlapping prescriptions of opioids and benzodiazepines: Evidence from Kentucky","volume":"243","author":"Nguyen","year":"2023","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2025.209725_bb0120","series-title":"Prescription drug abuse policy system: Prescription drug monitoring program: PDMP implementation dates","author":"PDAPS","year":"2023"},{"key":"10.1016\/j.josat.2025.209725_bb0125","series-title":"Drilling into the DEA\u2019s pain pill database","author":"Rich","year":"2019"},{"issue":"10","key":"10.1016\/j.josat.2025.209725_bb0130","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1001\/jamainternmed.2015.3931","article-title":"Effect of Florida\u2019s prescription drug monitoring program and pill mill laws on opioid prescribing and use","volume":"175","author":"Rutkow","year":"2015","journal-title":"JAMA Internal Medicine"},{"issue":"C","key":"10.1016\/j.josat.2025.209725_bb0135","article-title":"Can policy affect initiation of addictive substance use? Evidence from opioid prescribing","volume":"76","author":"Sacks","year":"2021","journal-title":"Journal of Health Economics"},{"issue":"1","key":"10.1016\/j.josat.2025.209725_bb0140","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/coep.12586","article-title":"Must-access prescription drug monitoring programs and retail opioid sales","volume":"41","author":"Shakya","year":"2023","journal-title":"Contemporary Economic Policy"},{"issue":"3","key":"10.1016\/j.josat.2025.209725_bb0145","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/coep.12607","article-title":"The effect of prescription drug monitoring programs on county-level opioid prescribing practices and spillovers","volume":"41","author":"Shakya","year":"2023","journal-title":"Contemporary Economic Policy"},{"issue":"1","key":"10.1016\/j.josat.2025.209725_bb0155","doi-asserted-by":"crossref","DOI":"10.1186\/s12245-017-0140-0","article-title":"The current utilization and perceptions of prescription drug monitoring programs among emergency medicine providers in Florida","volume":"10","author":"Young","year":"2017","journal-title":"International Journal of Emergency Medicine"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875925001043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T22:53:38Z","timestamp":1749596018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875925001043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":30,"alternative-id":["S2949875925001043"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2025.209725","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription opioid spillovers: Retail pharmacy level analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2025.209725","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"209725"}}